Oral Sub mucous Fibrosis (OSMF) is essentially an imbalance between collagen metabolism and wound healing mechanism induced by arecanut chewing habit. Clinically the disease progresses in stages with patients presenting with burning sensation, intolerance to spicy food, vesicles particularly on the palate, ulceration and dryness of the mouth , fibrosis of the oral mucosa, leading to lips, tongue, and palate rigidity and finally trismus. As the disease is progressively debilitating and has potential to turn in to malignant cancer a study was designed to assess if there any tissue or saliva markers that can be assessed for early diagnosis and indicate malignant transformation if any. Participants who had OSMF and habit history, patients without OSMF but habit history formed the case group where as normal patients without OSMF and no habit history were in control group. Eligible candidates who consented to participate in study were subjected to biopsy procedure and also their saliva samples were collected. Biopsy samples were subjected to immunohistochemistry (IHC) and polymerase chain reaction (PCR) to assess the EMT markers like vimentin, e-cadherin and collagen IV. miRNA copies were extracted from saliva and were subjected RT-PCR. Research question was: 1. Is EMT a positive signature in OSMF. 2. Does histopathological grading and dysplasia in OSMF have any correlation with EMT. 3. Can aberrant EMT markers be a reliable indicator for risk assessment of early malignant transformation. 4. Can expression of mi RNA 21 in saliva predict the disease severity and more importantly assess risk of early malignant transformation in OSMF.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Change in Expression of E-cadherin levels in all the groups in IHC
Timeframe: 10 days from sample collection
Change in Expression of vimentin levels in all the groups in IHC
Timeframe: 10 days from sample collection
Change in Expression of collagen IV levels in all the groups in IHC
Timeframe: 10 days from sample collection
Change in Expression of miRNA 21 in all three groups using Real Time-PCR
Timeframe: 10 days from sample collection
CHange in E cadherin levels in PCR
Timeframe: 20 days after sample collection
Change in vimentin levels in PCR
Timeframe: 20 days after sample collection